NEW YORK CITY, NY / ACCESS Newswire / February 18, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of ...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pliant Therapeutics, Inc. ("Pliant" or "the Company") (NASDAQ: ...

Trimming the fat is one thing, but it’s another to make slapdash cuts to agencies responsible for flight safety, nuclear ...

Norms recognized for decades in Washington by both parties no longer appear to apply to the Trump White House, former ...

Sofia takes a picture of Ingrid, her summer friend, at her sewing table. “Your August in Almeria…” murmurs Ingrid (a ...

The experts will assess unblinded data from BEACON-IPF to figure out why a data safety monitoring board recommended ...

Equities researchers at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Pliant Therapeutics in a report released on Monday, February 10th. HC Wainwright analyst E. Arce ...

Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) have been given an average rating of “Hold” by the eleven analysts that are presently covering the company, Marketbeat reports.

NEW YORK CITY, NY / ACCESS Newswire / February 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...

Henry Gosebruch, Neumora’s CEO since 2023, will depart. Elsewhere, Biogen dropped two antisense drugs in a pipeline cull and Voyager hit a setback for its ALS gene therapy.

Pliant Therapeutics shares were up 23% to $3.34 after the company said an independent Data Safety Monitoring Board is allowing it to begin the assembly of an outside expert panel to review unblinded ...